Research: Can newly-public biotech succeed at translational science? by Laura McNamee and Fred Ledley
Early-stage biotech companies play a critical role in the entrepreneurial ecosystem that is expected to develop commercial products from nascent scientific discoveries. Recent research from the Center for Integration of Science and Industry suggests that companies in the IPO “class of 2000” were ineffective in developing therapeutic products and asks whether the business models of newly-public biotech companies are up to the task.
Research: Are there patterns to successful biotech innovation?
Innovation in biotechnology is often portrayed as being wildly complex and unpredictable. Recent research from the Center for Integration of Science and Industry suggests that there are patterns in the timelines of technological maturation and successful development of therapeutic biotechnologies that are predictable from innovation theory.
Research: Why commercialization of gene therapy stalled
It has been 40 years since recombinant technologies first enabled consideration of gene therapy for human disease, and 30 years since the first gene therapy companies were formed. Yet, there are no gene therapies on the market in the US or EU. A recent research paper from the Center for Integration of Science and Industry explores how asynchrony between capital investments and the maturation of gene therapy technologies may have contributed to this delay.